Efficacy and Safety of Phentermine/Topiramate in Youth with Hypothalamic Obesity

Phase 2

Recruiting

• Conditions: Hypothalamic Obesity; Hypothalamic Tumor; Craniopharyngioma
• Interventions: Drug: Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]; Other: Placebo

• Registration Number: NCT06299891
• Lead Sponsor: Seattle Children's Hospital

Brief Summary

Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine/topiramate (Ph/T) that is FDA-approved for "common" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph/T-induced decrease in appetite and increase in alertness.

Preliminary assessments of safety, adverse events, dosing (Aim 1), as well as of efficacy (% BMI loss, Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 placebo-controlled clinical trial in 12-28-year-old individuals with HO.

Detailed Description

STUDY OVERVIEW This is a two-center, double-blind (participant and assessor), randomized, parallel-arm 28-week clinical phase II trial, comparing changes from pre- to post treatment in two study arms of active drug (Qsymia®) vs. placebo capsules. Twenty-four 12-28-year-old participants will be randomized 1:1 into the two intervention groups. The study will have a single central IRB (CHOP).

In this pilot trial, the objective is to gather key preliminary data about phentermine/topiramate (Ph/T), a promising option containing a sympathomimetic amine (Ph) combined with an appetite-suppressive epilepsy drug (T) that is FDA-approved for "common" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph/T-induced decrease in appetite and increase in alertness. Preliminary assessments of safety and dosing (adverse events and maximum tolerated dose - Aim 1), as well as of efficacy (% BMI loss - Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 randomized placebo-controlled clinical trial in 12-28-year-old individuals with HO. The FDA-approved dose titration will be followed. Other efficacy and mechanistic outcomes will be measured as well.

Specific Aims:

Aim 1: To assess safety and maximum tolerated dose of Ph/T. Main outcomes: treatment-emergent adverse events (including any during withdrawal), maximum tolerated dose (weeks 0 to 28).

Aim 2: To estimate the treatment effect of Ph/T with respect to weight loss in individuals with HO. Main outcome: % change in BMI (week 0 to 28) in response to Ph/T vs. placebo.

Study Approach:

Recruitment. Subjects will be required to travel to one of the two research sites (Seattle WA; Philadelphia PA). Each subject will be treated for 28 weeks plus 1 week of an appropriate taper in those participants who reached the highest dose at titration.

Participants will be pre-screened for eligibility via medical record review. Once written informed consent is obtained, eligibility will be confirmed.

Randomization. Eligible subjects will be assigned treatment using a permuted-block randomization (1:1) to drug vs. placebo for 28 weeks with varying block sizes constructed by the CHOP study statistician.

Study visits. Each participant will have a screening visit and 5 in-person study visits: Weeks 1 (baseline), 3, 14, 16, 28 (end of randomized trial). There will be a remote contact one week (+/- 3 days) after dose initiation and/or dose escalation to assess dose tolerability. The remote contact at 29 weeks will be performed to assess for any withdrawal effects and will be done in-person if there are any safety concerns that are most appropriately assessed in person. Visits at 1 and 28 weeks will be used for main outcome collection. Interim visits are required for assessment of dose escalation. Weeks 3 and 16 visits could be done remotely to reduce burden, in particular for individuals traveling from a distance, if participants prefer and have no concerning safety signals. Participants will be compensated for their time and travel. Efforts will be made to schedule study appointments at times that will accommodate participants' schedules.

Main outcome for Aim 1: Safety, as assessed by systematic collection of treatment-emergent adverse events using a safety monitoring uniform report form (SMURF), with adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Secondary outcome for Aim 1: Maximum tolerated dose of Ph/T, as defined by the dose of Ph/T that the participant is continuing to take at the week 28 visit, reflecting any dose individualization.

Main outcome for Aim 2: % change in BMI between weeks 1 (baseline) and week 28 (end of treatment).

Key secondary outcomes for Aim 2 (all assessed as change between weeks 1 and 28): proportion of participants who achieve at least 2.5% BMI reduction, proportion of participants who achieve at least 5% BMI reduction, change in fat mass and visceral fat (as assessed by DXA) from Baseline to Week 28.

Study Timeline

• Study First Submitted: 2024-03-01
• Study First Submitted QC: 2024-03-01
• Study First Posted: 2024-03-08
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-05
• Last Update Posted: 2025-02-10
• Study Start: 2025-03-01
• Primary Completion: 2026-05-31
• Study Completion: 2026-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Males and Females; Ages 12-28 years (inclusive)
2. History of rapid weight gain related to tumor onset or treatment, as assessed by an experienced endocrinologist (for example, change in BMI z-score > 0.2 and/or BMI +5% during the first 6 months following tumor treatment)
3. Obesity (BMI > 95th%ile for age/sex using CDC 2000 reference for under 18; BMI > 30 kg/m2 for 18+ years)
4. Recent evidence of hypothalamic injury by brain MRI with central review; >6 months status-post definitive therapy (surgery, chemotherapy, or radiation); no major operations/surgeries planned during the study period.
5. Stable on pituitary replacement* and/or appetite-modulating medications (including stimulants) for at least 2 months. *Adjustments of less than 25% (<25%) are permitted to hydrocortisone, growth hormone or thyroid hormone. Sex steroids and DDAVP are exempt.
6. Post-menarchal females must use a highly effective form of contraception, unless hypogonadotropic hypogonadism is documented. All participating females will have pregnancy testing as outlined in the protocol.
7. Participants must be able to communicate well with the investigative team, must comply with requirements of the study, and be able to provide written informed consent and/or assent for individuals less than 18y with consent of a parent/legal guardian.

Exclusion Criteria

1. Contraindication to Phentermine or Topiramate, as assessed using current package inserts. Including: History of glaucoma and known hyperthyroidism.
2. Known history of metabolic acidosis, low bicarbonate on screening laboratory (below lower limit of normal), or clinically significant bone disease requiring medication (not calcium or vitamin D).
3. Current or recent (<14 days) use of monoamine oxidase inhibitor.
4. Known hypersensitivity to sympathomimetic amines.
5. Clinically significant cardiovascular conditions, as defined as any of the following: i) abnormal blood pressure, defined as: under 13y, 95th%ile +12 mm Hg or > 140/90, whichever is lower; 13y and older, > 140/90 ; ii) history of cardiac arrhythmia or arrhythmia detected on screening ECG; iii) history of heart failure and/or cardiomyopathy; iv) prolonged QTc interval (QTc > 460 msec), and/or long QT syndrome phenotype and/or positive genotype for long QT syndrome pathogenic; v) history of cardiac disease including coronary artery disease.
6. Females who are pregnant, breastfeeding, or planning to become pregnant during the trial.
7. "Brittle" diabetes insipidus (in the opinion of the referring endocrinologist, e.g. requiring frequent hospitalizations and/or frequent abnormal sodium values).
8. Diabetes mellitus requiring insulin/secretagogue. HbA1c > 8.5% at Screening.
9. Clinically significant liver disease and/or known severe hepatic impairment. ALT > 3 x Upper Limit of Normal (ULN) AST > 3 x ULN
10. Clinically significant kidney disease. GFR<60 ml/min/1.73m2
11. History of seizure in the 12 months prior to Screening.
12. History of substance abuse, depression of moderate or greater severity, psychiatric disorder and/or suicidality.
13. History of abdominal surgery including gastric bypass.
14. Current use of supra-physiologic steroids.
15. History of allergy or sensitivity to test agents. Including individuals with known aspirin allergy or hypersensitivity and/or known allergy to FD&C Yellow No. 5 (tartrazine).
16. Concurrent use carbonic anhydrase inhibitor.
17. New weight management medication (or more than 5% decrease in weight over prior 2 months on any current, stable regimen), new stimulant, and/or investigational medication within 2 months prior to Screening, and/or plans to initiate new weight management regimen.
18. Cognitive impairment that, in the opinion of the investigator, precludes participation in the study.
19. Individuals considered, in the Investigator's opinion, otherwise not suitable to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Drug Intervention	Phentermine / Topiramate Extended Release Oral Capsule [Qsymia]	Active drug dose escalation and adjustment: The drug had been used in adolescents with obesity before. For this trial, the FDA approved dose titration will be followed until the highest tolerable dose is reached.
Placebo	Placebo	Matching placebo using capsules matching the appearance of the active drug.

Primary Outcome Measures

Name	Time	Method
Treatment-emergent adverse events	From baseline to completion of week 28	Incidence of treatment-emergent adverse events including any during withdrawal in study drug vs. placebo.

Secondary Outcome Measures

Name	Time	Method
Maximum tolerated dose	Week 0 to 28	Maximum tolerated dose achieved by the end of the study in study drug vs. placebo.
% change in BMI	Week 0 to 28	% change in BMI in response to study drug vs. placebo.
Change in hunger	Week 0 to 28	Daily assessment of hunger by questionnaire scores will be recorded prior to the patient's first meal of the day.
Change in energy intake	Week 0 to 28	Patient's dietary intake via the Automated Self-Administered 24-Hour Dietary Recall.
Proportion of individuals who experience 5% decrease in BMI	Week 0 to 28	Proportion of individuals who experience 5% decrease in BMI in response to study drug vs. placebo.
Proportion of individuals who experience 2.5% decrease in BMI	Week 0 to 28	Proportion of individuals who experience 2.5% decrease in BMI in response to study drug vs. placebo
Change in body fat mass	Week 0 to 28	Change in body fat mass via DXA in response to study drug vs. placebo.
Change in visceral fat mass	Week 0 to 28	Change of visceral fat mass in response to study drug vs. placebo via DXA.

Trial Locations

Locations (2)

Seattle Children's; 🇺🇸 Seattle, Washington, United States

The Children's Hospital of Philadelphia; 🇺🇸 Philadelphia, Pennsylvania, United States